Exelixis Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
1,077
- Stock Symbol
-
EXEL
- Investments
-
5
- Share Price
-
$69.00
- (As of Friday Closing)
Exelixis General Information
Description
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Contact Information
Website
www.exelixis.comCorporate Office
- 1851 Harbor Bay Parkway
- Alameda, CA 94502
- United States
Corporate Office
- 1851 Harbor Bay Parkway
- Alameda, CA 94502
- United States
Exelixis Stock Performance
As of 13-Nov-2026, Exelixis’s stock price is $69.00. Its current market cap is $16.8B with 244M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $69.00 | $69.84 | $39.71 - $73.69 | $16.8B | 244M | 2.41M | $3.46 |
Exelixis Financials Summary
As of 30-Sep-2026, Exelixis has a trailing 12-month revenue of $2.5B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 13,799,473 | 10,939,284 | 8,515,065 | 6,547,740 |
| Revenue | 2,496,861 | 2,320,126 | 2,168,701 | 1,830,208 |
| EBITDA | 1,031,573 | 901,093 | 633,287 | 196,695 |
| Net Income | 885,140 | 782,570 | 521,267 | 207,765 |
| Total Assets | 2,513,489 | 2,844,423 | 2,947,690 | 2,942,357 |
| Total Debt | 162,201 | 173,038 | 190,823 | 189,944 |
Exelixis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Exelixis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Exelixis Comparisons
Industry
Financing
Details
Exelixis Competitors (100)
One of Exelixis’s 100 competitors is Arcutis Biotherapeutics, a Formerly VC-backed company based in Westlake Village, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics | Formerly VC-backed | Westlake Village, CA | ||||
| Tyra Biosciences | Formerly VC-backed | Carlsbad, CA | ||||
| Inhibrx | Formerly VC-backed | La Jolla, CA | ||||
| Nuvalent | Formerly VC-backed | Cambridge, MA | ||||
| Macrogenics | Formerly VC-backed | Rockville, MD |
Exelixis Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Exelixis Patents
Exelixis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026222290-A1 | Methods for treating neuroendocrine tumors with zanzalintinib | Pending | 17-Apr-2025 | ||
| WO-2026198879-A1 | Antibody-drug conjugates and methods of their use | Pending | 21-Mar-2025 | ||
| WO-2026188090-A1 | 5t4 antibody drug conjugates and methods of their use | Pending | 07-Mar-2025 | ||
| WO-2026030408-A1 | Methods of use of agents that bind to nkg2a and pd-l1 | Pending | 31-Jul-2024 | ||
| AU-2025261354-A1 | Heterocyclic inhibitors of ubiquitin specific protease 1 (usp1) in combination with additional agents for use in the treatment of cancer | Pending | 26-Apr-2024 |
Exelixis Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Exelixis Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Exelixis Investments & Acquisitions (5)
Exelixis’s most recent deal was a Merger/Acquisition with X-Ceptor Therapeutics for . The deal was made on 19-Oct-2004.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| X-Ceptor Therapeutics | 19-Oct-2004 | Merger/Acquisition | Drug Discovery | ||
| Gentris | 01-Oct-2002 | Early Stage VC | Practice Management (Healthcare) | ||
| Genomica | 09-Jan-2002 | Merger/Acquisition | Medical Records Systems | ||
| Artemis Pharmaceuticals | 01-Jan-2001 | Merger/Acquisition | Drug Discovery | ||
| Exelixis Plant Sciences | 08-Dec-2000 | Merger/Acquisition | Other Agriculture |
Exelixis ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
25.09 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Exelixis Exits (1)
Exelixis’s most recent exit was on 01-Oct-2002 from Gentris. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Gentris | 01-Oct-2002 | Completed |
|
Exelixis FAQs
-
When was Exelixis founded?
Exelixis was founded in 1994.
-
Where is Exelixis headquartered?
Exelixis is headquartered in Alameda, CA.
-
What is the size of Exelixis?
Exelixis has 1,077 total employees.
-
What industry is Exelixis in?
Exelixis’s primary industry is Drug Discovery.
-
Is Exelixis a private or public company?
Exelixis is a Public company.
-
What is Exelixis’s stock symbol?
The ticker symbol for Exelixis is EXEL.
-
What is the current stock price of Exelixis?
As of 13-Nov-2026 the stock price of Exelixis is $69.00.
-
What is the current market cap of Exelixis?
The current market capitalization of Exelixis is $16.8B.
-
What is Exelixis’s current revenue?
The trailing twelve month revenue for Exelixis is $2.5B.
-
Who are Exelixis’s competitors?
Arcutis Biotherapeutics, Tyra Biosciences, Inhibrx, Nuvalent, and Macrogenics are some of the 100 competitors of Exelixis.
-
What is Exelixis’s annual earnings per share (EPS)?
Exelixis’s EPS for 12 months was $3.46.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
